Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 15 Months, Double-Blind, Randomized Controlled Trial Comparing 20 Weeks of Two Dosages of Omalizumab to Placebo to Accelerate a Symptom-driven Oral Immunotherapy Schedule in Subjects Aged 6 to 25 Years With Multiple Food Allergies

NCT04045301 is registered in ClinicalTrials.gov with Philippe Bégin as lead sponsor.

NCT NCT04045301
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04045301 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 15 Months, Double-Blind, Randomized Controlled Trial Comparing 20 Weeks of Two Dosages of Omalizumab to Placebo to Accelerate a Symptom-driven Oral Immunotherapy Schedule in Subjects Aged 6 to 25 Years With Multiple Food Allergies
Lead sponsor
Philippe Bégin
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 11, 2019
Completion date
March 31, 2026
Enrollment
90 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

food ige-mediated allergy, immunotherapy, omalizumab, physiological effects of drugs